<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437229</url>
  </required_header>
  <id_info>
    <org_study_id>NKV100787</org_study_id>
    <nct_id>NCT00437229</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety &amp; Interaction Between GW679769, Dexamethasone, &amp; Ondansetron When Taken by Healthy Adults</brief_title>
  <official_title>An Open-Label, Phase I Study to Assess the Pharmacokinetic Interaction Between Repeat Doses of Oral Casopitant and Intravenous and Oral Doses of Dexamethasone and Intravenous and Oral Doses of Ondansetron When Administered in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GW679769 may affect liver enzymes that metabolize dexamethasone and ondansetron. This study
      is designed to test the safety and the extent of the GW679769 affect on dexamethasone and
      ondansetron levels in humans.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 19, 2007</start_date>
  <completion_date type="Actual">May 15, 2007</completion_date>
  <primary_completion_date type="Actual">May 15, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Period 1 &amp; 2: Plasma levels of casopitant, dexamethasone, &amp; ondansetron will be checked on Day 1, 2 and/or 3. Part B: Period 1, 2 &amp; 3: Plasma levels of casopitant, dexamethasone, &amp; ondansetron will be checked on Day 1, 2 and/or 3.</measure>
    <time_frame>checked on Day 1, 2 and/or 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety is evaluated by: Clinical Lab Tests done</measure>
    <time_frame>at Screening, Day -1 &amp; Followup.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitals Signs taken &amp; Adverse Events monitored</measure>
    <time_frame>at each visit starting at Day -1.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 lead ECGs &amp; Serum Pepsinogen level tests</measure>
    <time_frame>at Screening &amp; Followup.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Nausea and Vomiting, Chemotherapy-Induced</condition>
  <arm_group>
    <arm_group_label>Subjects in Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In PART A, subjects received Regimen A: oral casopitant alone (150 mg once daily [QD] Day 1, 50 mg QD Days 2 and 3); Regimen B: oral dexamethasone (20 mg QD Day 1 and 8 mg twice daily [BID] Days 2 and 3) and intravenous (IV) ondansetron (32 mg single-dose Day 1); and Regimen C: oral casopitant as in Regimen A, IV ondansetron as in Regimen B and a lower dose oral dexamethasone than in Regimen B (12 mg QD Day 1, 8 mg QD Days 2 and 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects in Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In PART B, subjects received Regimen D: oral casopitant alone (150 mg QD Day 1, 50 mg QD Days 2 and 3); Regimen E: IV dexamethasone (8 mg single-dose Day 1 only) and oral ondansetron (8 mg BID Days 1 to 3); and Regimen F: oral casopitant regimen as in Regimen D, and IV dexamethasone and oral ondansetron as in Regimen E.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Casopitant (GW679769) Oral Tablets</intervention_name>
    <description>Casopitant (GW679769) tablets will be available as white, film-coated tablets containing 50 mg of GW679769 as the mesylate salt for oral administration.</description>
    <arm_group_label>Subjects in Part B</arm_group_label>
    <arm_group_label>Subjects in Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>Dexamethasone will be available as 4 mg tablets for oral administration and injection for IV administration.</description>
    <arm_group_label>Subjects in Part B</arm_group_label>
    <arm_group_label>Subjects in Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>Ondansetron for oral use will be available as 8 mg tablets to be taken with 240 milliliters (mL) of water on an empty stomach. For IV use, ondansetron 32 mg will be infused intravenously over a period of 15 minutes.</description>
    <arm_group_label>Subjects in Part B</arm_group_label>
    <arm_group_label>Subjects in Part A</arm_group_label>
    <other_name>GW679769 Oral Tablets</other_name>
    <other_name>dexamethasone oral tablets &amp; intravenous</other_name>
    <other_name>ondansetron oral tablets &amp; intravenous</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult males or females

          -  Age: 18 to 55 years, inclusive

          -  A female subject who is non-childbearing potential or using acceptable contraceptive
             methods.

          -  Adequate organ systems function

          -  Able to swallow and retain oral medication

          -  Able to understand and comply with protocol requirements and instruction and is likely
             to complete the study.

        Exclusion Criteria:

          -  Cannot participation if subject has a clinically relevant abnormality, medical
             condition, or circumstance that makes them unsuitable for the study per the study
             doctor.

          -  History of drug or other allergy which, in the opinion of the Investigator,
             contraindicates participation.

          -  Use of an investigation drug within 28 days or 5 half-lives.

          -  Blood donation in excess of 500mL within 56 days prior to dosing or intends to donate
             within 30 days of the post-treatment follow-up visit.

          -  Presence of or suspected iron deficiency

          -  Positive stool for occult blood

          -  Female subject who is lactating

          -  Positive urine drug screen

          -  Positive for HIV antibody, hepatitis C antibody or hepatitis B surface antigen

          -  Use of tobacco-containing products within the past 12 months prior to screening

          -  History of drug or alcohol abuse or dependence within 6 months of screening

          -  History or presence of uncontrolled emesis

          -  Positive purified protein derivative (PPD) skin test for tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/NKV100787?search=study&amp;search_terms=100787#rs</url>
    <description>Results for study 100787 can be found on the GSK Clinical Study Register.</description>
  </link>
  <reference>
    <citation>Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, Blum R. Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer. 2009 Sep;17(9):1177-85. doi: 10.1007/s00520-008-0571-5. Epub 2009 Feb 10.</citation>
    <PMID>19205755</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2007</study_first_submitted>
  <study_first_submitted_qc>February 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2007</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW679769,</keyword>
  <keyword>Casopitant,</keyword>
  <keyword>Dexamethasone,</keyword>
  <keyword>Healthy Human Volunteer</keyword>
  <keyword>Ondansetron,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Casopitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

